Halozyme Therapeutics Inc (HALO)

[jamtomorrow2]

"There are now 268 combo trials involving Keytruda and 242 with Opdivo, of which 86 combine Opdivo with Yervoy. Keytruda’s dominance comes as the drug continues to impress in clinical trials
The number of studies combining anti-PD-1/PD-L1s with chemotherapy have surged, potentially spurred by Roche’s efforts with Tecentriq
The most popular indication for combinations is lung cancer, which makes up the biggest single market (16%), followed by melanoma and sarcoma (13%), which has so far showed the best efficacy for PD-1/PD-L1s
IO-IO combos also represent a significant part of the analysis. Keytruda, Opdivo and Tecentriq are in 56, 54 and 32 IO-IO combo studies respectively"

So HALO is involved in some of these combo trials. Let's take PEG and Keytruda as an example. What happens if a combo of Keytruda and another drug proves to be better than Keytruda alone. Where would that leave the PEG and Keytruda trial? On the shelf probably. HALO would then need to do another trial combining PEG with the other combo. This could be a never ending drain of an already huge potential black hole.